Ironically, I thought the biggest news affecting Ariad yesterday was actually the Crizotinib data...really impressive. I saw that one analyst put the market opportunity at $2.5 billion. Although it is way too early to know, given the resistance data released earlier this year, this could potentially have greater commercial value for Ariad than ponatinib.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.